Skip to content
Menu

Aclaris Begins Phase 2b Modzatinib Trial In Lichen Planus, Fast Track-Designated Dual ITK/JAK3 Inhibitor With Potential As First Mechanistically Complete Oral Therapy

Benzinga Newsdesk 2 days ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

- Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options --

- Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options -

- Unique Mechanism Targets Key Pathways Implicated in LP Pathology, T-cell Receptor Signaling Upstream and Effector Cytokine Signaling Downstream -

Read at benzinga.com